Evidence map›Paper›PMID 37993892›Full record

ArticleThrombosis journal2023

A comprehensive model for assessing and classifying patients with thrombotic microangiopathy: the TMA-INSIGHT score.

Vanessa Vilani Addad, Lilian Monteiro Pereira Palma, Maria Helena Vaisbich, Abner Mácola Pacheco Barbosa, Naila Camila da Rocha, Marilia Mastrocolla de Almeida Cardoso, Juliana Tereza Coneglian de Almeida, Monica Ap de Paula de Sordi, Juliana Machado-Rugolo, Lucas Frederico Arantes and 1 more

Open access · goldAbstract read
In one paragraph

Article in Thrombosis journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Guideline
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Vanessa Vilani AddadDepartment of Internal Medicine - UNESP, Univ Estadual Paulista, Rubião Jr, s/n, Botucatu/SP, 18618-687, Brazil.ORCID http://orcid.org/0000-0002-9322-3849
Lilian Monteiro Pereira PalmaDepartment of Pediatrics, Universidade Estadual de Campinas, R. Tessália Vieira de Camargo, 126 - Cidade Universitária, Campinas/SP, 13083-887, Brazil.ORCID http://orcid.org/0000-0002-0334-8470
Maria Helena VaisbichPediatric Nephrology Service, Child Institute, University of São Paulo, Av. Dr. Enéas Carvalho de Aguiar, 647, São Paulo, SP, 05403-000, Brazil.ORCID http://orcid.org/0000-0002-6084-7831
Abner Mácola Pacheco BarbosaDepartment of Internal Medicine - UNESP, Univ Estadual Paulista, Rubião Jr, s/n, Botucatu/SP, 18618-687, Brazil.ORCID http://orcid.org/0000-0003-3668-8911
Naila Camila da RochaDepartment of Internal Medicine - UNESP, Univ Estadual Paulista, Rubião Jr, s/n, Botucatu/SP, 18618-687, Brazil.ORCID http://orcid.org/0000-0002-1684-2574
Marilia Mastrocolla de Almeida CardosoHealth Technology Assessment Center of Hospital das Clínicas - HCFMB, Botucatu, SP, Brazil.ORCID http://orcid.org/0000-0002-6231-5425
Juliana Tereza Coneglian de AlmeidaHealth Technology Assessment Center of Hospital das Clínicas - HCFMB, Botucatu, SP, Brazil.ORCID http://orcid.org/0000-0001-8865-0398
Monica Ap de Paula de SordiHealth Technology Assessment Center of Hospital das Clínicas - HCFMB, Botucatu, SP, Brazil.ORCID http://orcid.org/0000-0003-3621-3414
Juliana Machado-RugoloHealth Technology Assessment Center of Hospital das Clínicas - HCFMB, Botucatu, SP, Brazil.ORCID http://orcid.org/0000-0003-3984-4959
Lucas Frederico ArantesHealth Technology Assessment Center of Hospital das Clínicas - HCFMB, Botucatu, SP, Brazil.ORCID http://orcid.org/0000-0002-4946-5189
Luis Gustavo Modelli de AndradeDepartment of Internal Medicine - UNESP, Univ Estadual Paulista, Rubião Jr, s/n, Botucatu/SP, 18618-687, Brazil. Gustavo.modelli@unesp.br.ORCID http://orcid.org/0000-0002-0230-0766
Hospital das Clínicas da Universidade Federal de Minas Gerais · BRUniversidade Estadual Paulista (Unesp) · BRUniversidade de São Paulo · BRUniversidade Estadual de Campinas (UNICAMP) · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThrombotic Microangiopathy (TMA) is a syndrome characterized by the presence of anemia, thrombocytopenia and organ damage and has multiple etiologies. The primary aim is to develop an algorithm to classify TMA (TMA-INSIGHT score).

methodsThis was a single-center retrospective cohort study including hospitalized patients with TMA at a single center. We included all consecutive patients diagnosed with TMA between 2012 and 2021. TMA was defined based on the presence of anemia (hemoglobin level < 10 g/dL) and thrombocytopenia (platelet count < 150,000/µL), signs of hemolysis, and organ damage. We classified patients in eight categories: infections; Malignant Hypertension; Transplant; Malignancy; Pregnancy; Thrombotic Thrombocytopenic Purpura (TTP); Shiga toxin-mediated hemolytic uremic syndrome (STEC-SHU) and Complement Mediated TMA (aHUS). We fitted a model to classify patients using clinical characteristics, biochemical exams, and mean arterial pressure at presentation.

resultsWe retrospectively retrieved TMA phenotypes using automatic strategies in electronic health records in almost 10 years (n = 2407). Secondary TMA was found in 97.5% of the patients. Primary TMA was found in 2.47% of the patients (TTP and aHUS). The best model was LightGBM with accuracy of 0.979, and multiclass ROC-AUC of 0.966. The predictions had higher accuracy in most TMA classes, although the confidence was lower in aHUS and STEC-HUS cases.

conclusionSecondary conditions were the most common etiologies of TMA. We retrieved comorbidities, associated conditions, and mean arterial pressure to fit a model to predict TMA and define TMA phenotypic characteristics. This is the first multiclass model to predict TMA including primary and secondary conditions.

Indexed as

Atypical hemolytic uremic syndromeComplement mediated TMAShiga toxin-mediated hemolytic uremic syndromeThrombotic microangiopathyThrombotic Thrombocytopenic Purpura

Identifiers

PMID37993892
PMCPMC10664252
OpenAlexW4388904171

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.